RU2015140499A - COMPOSITION FOR USE IN TREATMENT OF OVARIAN POLYCYSTOSIS SYNDROME - Google Patents

COMPOSITION FOR USE IN TREATMENT OF OVARIAN POLYCYSTOSIS SYNDROME Download PDF

Info

Publication number
RU2015140499A
RU2015140499A RU2015140499A RU2015140499A RU2015140499A RU 2015140499 A RU2015140499 A RU 2015140499A RU 2015140499 A RU2015140499 A RU 2015140499A RU 2015140499 A RU2015140499 A RU 2015140499A RU 2015140499 A RU2015140499 A RU 2015140499A
Authority
RU
Russia
Prior art keywords
composition
use according
lipoic acid
monacolin
polycystic ovary
Prior art date
Application number
RU2015140499A
Other languages
Russian (ru)
Inventor
Лоренцо СЕКОНДИНИ
Луиджи АМЕЛОТТИ
Original Assignee
Лаборест Италия С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборест Италия С.П.А. filed Critical Лаборест Италия С.П.А.
Publication of RU2015140499A publication Critical patent/RU2015140499A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Materials For Photolithography (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (18)

1. Состав, содержащий смесь, содержащую следующие соединения:1. A composition containing a mixture containing the following compounds: (1) соединение на основе красного ферментированного риса (Monascus purpureus), титрованное по монаколину, и(1) a compound based on red fermented rice (Monascus purpureus) titrated according to monacolin, and (2) соединение, представляющее собой липоевую кислоту или ее производное,(2) a compound representing lipoic acid or its derivative, или альтернативно состоящую из них,or alternatively consisting of them, для применения в:for use in: (а) профилактическом лечении синдрома поликистоза яичников и метаболических расстройств, являющихся следствием синдрома поликистоза яичников или связанных с ним,(a) the prophylactic treatment of polycystic ovary syndrome and metabolic disorders resulting from or associated with polycystic ovary syndrome, (б) лечении, направленном на снижение и/или устранение симптомов синдрома поликистоза яичников и метаболических расстройств, являющихся следствием синдрома поликистоза яичников или связанных с ним.(b) treatment aimed at reducing and / or eliminating the symptoms of polycystic ovary syndrome and metabolic disorders resulting from or associated with polycystic ovary syndrome. 2. Состав для применения по п. 1 для снижения содержания липидов и степени гирсутизма у инсулинрезистентных и гиперандрогенных женщин, пораженных синдромом поликистоза яичников, PCOS.2. The composition for use according to claim 1 to reduce the lipid content and the degree of hirsutism in insulin-resistant and hyperandrogenic women affected by polycystic ovary syndrome, PCOS. 3. Состав для применения по п. 1, где указанная смесь содержит следующие соединения:3. The composition for use according to claim 1, wherein said mixture contains the following compounds: (1) соединение на основе красного ферментированного риса (Monascus purpureus), титрованное по монаколину,(1) a compound based on red fermented rice (Monascus purpureus) titrated according to monacolin, (2) соединение, представляющее собой D-хироинозит и/или миоинозит, и(2) a compound representing D-chiroinositis and / or myoinositis, and (3) соединение, представляющее собой липоевую кислоту или ее производное,(3) a compound representing lipoic acid or its derivative, или альтернативно состоит из них.or alternatively consists of them. 4. Состав для применения по п. 1, где красный ферментированный рис (Monascus purpureus), титрованный по монаколину, имеет титр монаколина, составляющий от 3% до 10% по монаколину.4. The composition for use according to claim 1, wherein the red fermented rice (Monascus purpureus) titrated according to monacolin has a monacolin titer of 3% to 10% for monacolin. 5. Состав для применения по п. 1, где указанная альфа-липоевая кислота присутствует в виде рацемической смеси 50/50 R-(+)-альфа-липоевая кислота/S-(-)-альфа-липоевая кислота.5. The composition for use according to claim 1, wherein said alpha lipoic acid is present as a racemic mixture of 50/50 R - (+) - alpha lipoic acid / S - (-) - alpha lipoic acid. 6. Состав для применения по п. 1, где указанная альфа-липоевая кислота представлена в микроинкапсулированной форме или в форме с покрытием.6. The composition for use according to claim 1, wherein said alpha lipoic acid is present in microencapsulated form or in coated form. 7. Состав для применения по п. 1, находящийся в твердой форме для перорального введения, предпочтительно в виде таблеток или гранул для пакетов-саше или твердых капсул.7. The composition for use according to claim 1, which is in solid form for oral administration, preferably in the form of tablets or granules for sachets or hard capsules. 8. Состав для применения по любому из п.п. 1-7 в виде фармацевтической композиции или продукта-добавки.8. The composition for use according to any one of paragraphs. 1-7 in the form of a pharmaceutical composition or additive product.
RU2015140499A 2013-03-07 2014-03-07 COMPOSITION FOR USE IN TREATMENT OF OVARIAN POLYCYSTOSIS SYNDROME RU2015140499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2013A000349 2013-03-07
IT000349A ITMI20130349A1 (en) 2013-03-07 2013-03-07 COMPOSITION FOR USE IN THE TREATMENT OF THE POLICISTIC OVEN SYNDROME
PCT/IB2014/000257 WO2014135956A1 (en) 2013-03-07 2014-03-07 Composition for use in the treatment of polycystic ovary syndrome

Publications (1)

Publication Number Publication Date
RU2015140499A true RU2015140499A (en) 2017-04-12

Family

ID=48579220

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015140499A RU2015140499A (en) 2013-03-07 2014-03-07 COMPOSITION FOR USE IN TREATMENT OF OVARIAN POLYCYSTOSIS SYNDROME

Country Status (5)

Country Link
EP (1) EP2964207A1 (en)
BR (1) BR112015021722A2 (en)
IT (1) ITMI20130349A1 (en)
RU (1) RU2015140499A (en)
WO (1) WO2014135956A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7203521B2 (en) * 2018-06-29 2023-01-13 小林製薬株式会社 Compositions containing D-chiro-inositol
MX2021005888A (en) 2018-11-26 2021-06-23 Procter & Gamble Solid pharmaceutical preparation containing lipoic acid and use thereof.
CN109517740B (en) * 2018-12-05 2020-11-27 广东天益生物科技有限公司 Monascus purpureus mutant strain, water-soluble functional red yeast and preparation method and application thereof
IT201900025063A1 (en) * 2019-12-20 2021-06-20 Idi Integratori Dietetici Italiani S R L GASTRORESISTANT COMPOSITIONS INCLUDING INOSITOL AND / OR SYLVESTRE GYMNEMA EXTRACT, THEIR PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS AND THEIR USE
US11850218B2 (en) * 2022-05-17 2023-12-26 Provation Life LLC Nutraceutical compositions and methods for dietary alleviation of Polycystic Ovary Syndrome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1403587B1 (en) * 2010-12-17 2013-10-31 Laborest Italia S P A COMPOSITION FOR THE TREATMENT OF METABOLIC DISORDERS

Also Published As

Publication number Publication date
BR112015021722A2 (en) 2017-07-18
WO2014135956A1 (en) 2014-09-12
ITMI20130349A1 (en) 2014-09-08
EP2964207A1 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
RU2015140499A (en) COMPOSITION FOR USE IN TREATMENT OF OVARIAN POLYCYSTOSIS SYNDROME
RU2018114447A (en) INTRODUCTION OF CFTER DUTERED AMPLIFIERS
RU2019131148A (en) TREATMENT OF MALIGNANT TUMORS USING MODULATORS OF PI3-KINASE ISOFORM
BR112014028841A2 (en) process for preparing n- [5- (3,5-difluoro-benzyl) -1h-indazol-3-yl] -4- (4-methyl-piperazin-1-yl) -2- (tetrahydro-pyran -4-ylamino) -benzamide
EA201491060A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
WO2013066835A3 (en) Compounds and methods
WO2013066839A3 (en) Compounds and methods
EA201391561A1 (en) NEW CONNECTIONS-MODULATORS GPR-119
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
RU2018135921A (en) STABILIZED VANCOMYCIN COMPOSITIONS
MD20140072A2 (en) New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them
EA201490228A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
EA201491362A1 (en) ANESTHYZING COMPOUNDS AND METHODS OF THEIR APPLICATION
MX2014004858A (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies.
EA201391574A1 (en) PHARMACEUTICALLY ACCEPTABLE N- [2- (7-METHOXI-1-NAPHYL) ETHYL] ACETAMIDE AND THE METHODS OF THEIR PRODUCTION
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
EA201891804A1 (en) TETRACYCLINE CONNECTIONS
GEP201606598B (en) Heteroaromatic compounds as dopamine d1 ligands
EA201201294A1 (en) HYDROCHLORIDE AHOMELATIN HYDRATE AND ITS OBTAINING
BR112014003849A2 (en) vehicle frame and component design for efficient and compact packaging
WO2011123536A8 (en) Polycyclic tetracycline compounds
CA2899024C (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
RU2013130308A (en) COMPOSITION FOR TREATING METABOLIC DISORDERS
RU2019110980A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A 15-HEPC AND METHODS FOR TREATING ASTHMA AND LUNG DISEASES WITH THEIR APPLICATION
EA201600323A1 (en) DERIVATIVES OF PIPERAZINE AND THEIR APPLICATION AS A MEDICINE